Clinical Evaluation of Morcher Artificial Iris Diaphragms

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of Morcher iris diaphragms in the treatment of congenital and acquired aniridia. Morcher iris diaphragms are intraocular devices that are designed to provide an artificial pupil for patients suffering from partial or complete aniridia. These devices are constructed from clinical quality, ultraviolet light-absorbing, opaque black polymethylmethacrylate (PMMA). After surgical implantation, patients are monitored over the course of 1 year to measure any changes to visual acuity and improvements in light and glare sensitivity.

Clinical Trial Description

Aniridia is a condition in which the iris, the colored portion of the eye, is either partially or completely absent. The iris is responsible for regulating the amount of light entering the eye by adjusting the size of the pupil. Aniridia can either be a congenital condition, often a genetically-based abnormality affecting the formation of the iris, or it can be acquired by blunt trauma with or without rupture, penetrating trauma, or severe intraocular inflammation. Aniridia can also vary in the level of severity. A mild case might involve a thinner iris or iris remnant with a normal pupil. A severe case might involve complete absence of the iris or impairment of the muscles responsible for adjusting pupil size. Iris defects can occur without the loss of stromal tissue as well. In some cases, the iris pigment epithelium is missing. In other cases, holes are present in the iris or the pupil is chronically enlarged or mydriatic. People who suffer from iris defects also commonly suffer from other eye conditions. Common comorbidities include glaucoma, cataract, and nystagmus. Other structures in the eye are often affected, including the cornea, crystalline lens, zonules, and retina. Iris defects can cause severe visual disability if untreated. Common treatments for iris defects include the use of colored or tinted glasses or contact lenses to reduce the amount of light entering the eye. In this trial, several Morcher iris diaphragms are being evaluated as a potential treatment to improve the symptoms associated with aniridia and other iris defects. Morcher iris diaphragms are manufactured in Germany by Morcher GmbH [website: http:// www.morcher.com]. These devices have been utilized in Europe to treat aniridic patients for over 40 years. Additionally, these devices hold the European CE mark of conformity. When a patient is implanted with a Morcher iris device, surgery always involves additional standard of care surgical procedures. Typically, a device is implanted during cataract surgery along with an intraocular lens (IOL). Morcher devices can also be implanted during an IOL exchange with or without an anterior vitrectomy. All implantation procedures take place in an operating room under local or general anesthesia. In some cases, a Morcher iris reconstruction lens containing both an artificial iris and a lens is implanted. Also, depending on the condition of the eye, the lens and iris device may need to be sutured to the sclera, the white portion of the eye. All patients undergoing surgery are prescribed 2 different eye drops, an antibiotic and a corticosteroid. These medications are used for up to 6 weeks following implantation of the device. There are 5 postoperative follow-up visits that each patient must complete. Visits occur at specific intervals over the course of a 1-year period. At each visit, standard of care procedures are performed and, at certain time points during the follow-up interval, digital photos and endothelial cell counts are obtained. In instances where both eyes are implanted, surgery for the second eye is scheduled 6 months or more later. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00812708
Study type	Interventional
Source	University of California, Los Angeles
Contact
Status	Completed
Phase	N/A
Start date	April 9, 2003
Completion date	December 7, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00758108` - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Not yet recruiting	`NCT06412718` - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Recruiting	`NCT05400590` - Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
Recruiting	`NCT05044598` - RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy	Phase 1/Phase 2
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT00001161` - Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens	N/A
Enrolling by invitation	`NCT03461978` - Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures	N/A
Recruiting	`NCT05954403` - National Cohort on Congenital Defects of the Eye
Completed	`NCT02647359` - Study of Ataluren in Participants With Nonsense Mutation Aniridia	Phase 2
Completed	`NCT03581864` - Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
Recruiting	`NCT05562115` - Proteomic Study of Tears From Patients With a PAX6 Mutation	N/A
Completed	`NCT00265590` - Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia	N/A
Withdrawn	`NCT04117880` - A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia	Phase 2
Active, not recruiting	`NCT00503893` - Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
Completed	`NCT01644552` - Positive Angle Kappa